- 如果您对该产品感兴趣的话，可以
- 产品名称：Anti-SLC35C2抗体
- 产品型号：溶质载体蛋白家族35成员C2抗体
- 产品展商：KALANG
- 产品文档：无相关文档
- 发布时间：2018-08-16
- 在线询价
简单介绍
Anti-SLC35C2抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-SLC35C2抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
产品描述
Rabbit Anti-SLC35C2
Cat. Number:
Anti-SLC35C2抗体KL-12118R
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
SLC35C2 (solute carrier family 35, member C2), also known as C20orf5, OVCOV1 or CGI-15, is a 365 amino acid multi-pass Anti-SLC35C2抗体membrane protein that belongs to the TPT transporter family and exists as multiple alternatively spliced isoforms. Expressed ubiquitously and functionally induced in hypoxic trophoblast cells, SLC35C2 plays a role in the cellular response to tissue hypoxia and is thought to be involved in the pathogenesis of ovarian cancer. The gene encoding SLC35C2 maps to human chromosome 20, which houses over 600 genes some of which are associated with Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis, spinal muscular atrophy, ring chromosome 20 epilepsy syndrome and Alagille syndrome. Additionally, chromosome 20 contains a region with numerous genes which are thought important for seminal production and may be potential targets for male contraception.
Also known as:
BA394O2.1; C20orf5; CGI-15; Anti-SLC35C2抗体FLJ37039; MGC20633; MGC32079; MGC39183; Ovarian cancer-overexpressed gene 1 protein; OVCOV1; S35C2_HUMAN; SLC35C2; Solute carrier family 35 member C2.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Anti-SLC35C2抗体Chicken, Pig, Cow, Horse, Rabbit, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human SLC35C2.
●
Predicted Molecular Weight: 40kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-SLC35C2抗体
Optimal working dilutions must be determined by the end user.
